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Abstract: Dementia is a clinical syndrome of widespread progressive deterioration of cognitive 
abilities and normal daily functioning. These cognitive and behavioral impairments pose 
considerable challenges to individuals with dementia, along with their family members and 
caregivers. Four primary dementia classifications have been defined according to clinical and 
research criteria: 1) Alzheimer’s disease; 2) vascular dementias; 3) frontotemporal dementias; 
and 4) dementia with Lewy bodies/Parkinson’s disease dementia. The cumulative efforts of 
multidisciplinary healthcare teams have advanced our understanding of dementia beyond 
basic descriptions, towards a more complete elucidation of risk factors, clinical symptoms, 
and neuropathological correlates. The characterization of disease subtypes has facilitated 
targeted management strategies, advanced treatments, and symptomatic care for individuals 
affected by dementia. This review briefly summarizes the current state of knowledge and direc-
tions of dementia research and clinical practice. We provide a description of the risk factors, 
clinical presentation, and differential diagnosis of dementia. A summary of multidisciplinary 
team approaches to dementia care is outlined, including management strategies for the treatment 
of cognitive impairments, functional deficits, and behavioral and psychological symptoms of 
dementia. The needs of individuals with dementia are extensive, often requiring care beyond 
traditional bounds of medical practice, including pharmacologic and non-pharmacologic man-
agement interventions. Finally, advanced research on the early prodromal phase of dementia is 
reviewed, with a focus on change-point models, trajectories of cognitive change, and threshold 
models of pathological burden. Future research goals are outlined, with a call to action for social 
policy initiatives that promote preventive lifestyle behaviors, and healthcare programs that will 
support the growing number of individuals affected by dementia.
Keywords: dementia, Alzheimer’s disease, clinical features, multidisciplinary care, BPSD, 
prodromal dementia
Introduction
The clinical syndrome of dementia as a progressive deterioration of cognitive abili-
ties and functional impairments has been recognized for over a century; however it 
has only been understood within the context of its current characterization in the 
past few decades. In the early 20th century, a shift in the conceptualization of mental 
illness away from causation towards disease etiology occurred, with dementia being 
conceived as a direct effect of age-related processes. Alzheimer’s disease (AD) as 
a progressive neurodegenerative disorder did not emerge as a distinct entity until 
the mid-20th century, which led to the recognition of multiple disease states with 
unique etiologies. Contemporary dementia research has progressed rapidly on multiple 
fronts, including epidemiology, pathology, diagnosis, and treatment. As a result, four Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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primary dementia groupings have been defined according to 
clinical and research criteria: 1) Alzheimer’s disease (AD; 
including mixed-AD); 2) vascular dementias (VaD; including 
large and small vessel disease); 3) frontotemporal demen-
tias (FTD; including Pick’s disease, progressive nonfluent 
aphasia, and semantic dementia); and 4) dementia with 
Lewy bodies (DLB; including Parkinson’s disease dementia 
[PDD]). The cumulative efforts of multidisciplinary research 
teams across the world have advanced our understanding of 
dementia beyond basic descriptions of clinical symptoms 
and neuropathological correlates, towards a more complete 
elucidation of risk factors and underlying pathobiological 
disease mechanisms and, importantly, have led to targeted 
treatments, management, and care.
The needs of individuals affected by dementia are 
extensive, and the management of the clinical syndrome is 
complex, extending beyond traditional bounds of medical 
practice. Whereas medicine has historically focused on the 
effects of disease on the patient, dementia care requires a 
broader focus extending to family members, caregivers, and 
support networks. This broad-based approach to the care 
and management of dementia involves consideration of the 
quality of life for affected individuals to a greater extent 
than many other disease states. Dementia is characterized 
by significant impairments in multiple cognitive domains, 
functioning, and behavior, and places a tremendous burden 
not only on individuals, but also on society. Early detection 
and management may prevent overuse of costly healthcare 
resources and allow affected individuals and caregivers time 
to prepare for future medical, financial, and emotional chal-
lenges. Many of the most effective management approaches 
are nonpharmacologic, and provided by healthcare profes-
sionals from multiple disciplines. We are now entering an era 
of dementia care that will be based upon the identification of 
early disease markers and potentially modifiable risk factors, 
along with the application of novel diagnostic tools, treatment 
modalities, and care practices.
In this review, we briefly summarize the current state of 
knowledge and directions of research for dementia epidemi-
ology, its clinical presentation, multidisciplinary approaches 
to care, treatment options, management challenges, and 
future research goals.
Population aging and dementia 
epidemiology
Population aging and increased life expectancy has become a 
worldwide epidemiological phenomenon. Global projections 
for the number of older individuals ($65 years) are expected 
to increase from 420 million in 2000, to nearly 1 billion 
by 2030, with a corresponding increase in the proportion 
of older individuals rising from 7% to 12%.1,2 Developing 
countries will see the greatest rise in absolute numbers of 
older individuals, and will contribute to worldwide popula-
tion aging with an increase from 59% to 71%.3 Dementia is 
strongly associated with increasing age, and consequently 
neurodegenerative disorders are anticipated to pose signifi-
cant challenges to public healthcare systems worldwide in 
the coming decades.
The prevalence of dementia is also rising, particularly 
AD, which is the most common form of dementia accounting 
for approximately 60% of all cases.4,5 Worldwide, the global 
prevalence of dementia is estimated to be 3.9% in individuals 
over the age of 60 years, with regional prevalence rates of 
1.6% in Africa, 4.0% in China and Western Pacific Regions, 
4.6% in Latin America, 5.4% in Western Europe, and 6.4% 
in North America.3 Greater than 25 million people in the 
world are currently affected by dementia syndromes, with 
most individuals suffering from AD and vascular dementia 
(VaD) (Figure 1).4–6 Approximately 5 million new cases 
are estimated to occur each year, and the number of indi-
viduals with dementia is expected to double every 20 years 
 ( Figure 2).2,3,6
Risk factors, clinical presentation, 
and diagnosis of dementia
The clinical syndrome of dementia generally follows three 
primary expressions.7–10 First, a neuropsychological compo-
nent consisting of a range of cognitive impairments, often 
including: memory impairments (declarative and procedural 
memory problems), aphasias (either receptive or expressive 
language difficulties), apraxias (inability to carry out directed 
coordination of movements despite intact sensory and motor 
nervous systems), agnosias (inability to recognize specific 
elements of an individual’s environment or self), attentional 
difficulties (including sustained and divided attention), and 
executive functioning impairments (including difficulties 
Alzheimer’s disease
54%
Other dementias
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Figure 1 worldwide subtypes of late onset dementia ($65 years). 
Copyright © 2007, elsevier inc. Adapted with permission from Brookmeyer et al.6 
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with abstraction, cognitive flexibility, inhibition, planning, 
organizing, and adaptation to novel stimuli). The second pri-
mary expression of this syndrome is a neuropsychiatric ele-
ment with associated symptoms and behavioral disturbances. 
These psychiatric features are present in a substantial pro-
portion of affected individuals, and are commonly referred 
to as behavioral and psychological symptoms of dementia 
(BPSD). Common BPSD disturbances include depression, 
paranoid ideation, delusions, hallucinations, aggression, and 
wandering.11 The third primary clinical expression includes 
deficits in activities of daily living (ADL).8 In the early stages 
of dementia, impaired instrumental activities of daily liv-
ing (IADL) may be manifest including self-neglect of diet, 
personal hygiene, and common household tasks. Towards 
the later stages of dementia, basic activities of daily living 
(BADL) are often impaired, presenting with obvious prob-
lems in dressing, eating, and bathing.12,13
This triad of features is common to most dementias, with 
the differentiation of subtypes based on clinical presentation, 
the presence of comorbid symptoms, and other aspects of the 
individual’s history and examination.7,8,14 Individuals with 
dementia tend to present to specialist healthcare services (eg, 
neurologist, neuropsychologist, memory disorders clinic) only 
when symptoms begin to interfere with   everyday activities and 
functioning. Depending upon the stage of   disease progression, 
the patient is often unable to provide an accurate history and 
may deny any presence of impairments. Therefore, a detailed 
history from a reliable primary informant (eg, family, care-
giver) is essential to provide collateral information of previous 
baseline functioning, symptom onset, and supportive evidence 
of changes in cognitive and behavioral functioning.15 Depend-
ing on the dementia subtype, there is wide variability in rates 
of decline from person to person and in the rapidity with which 
the disease process develops. Nevertheless, all dementias are 
degenerative and progressive. Early detection and the dif-
ferential diagnosis of dementia subtype, disease complexity, 
and sequelae requires skilled clinical judgment and is based 
on multiple sources of information (see Figure 3).16
Mild cognitive impairment
Clinical AD is often preceded by a prodromal phase com-
monly referred to as mild cognitive impairment (MCI).17 
Despite several operational definitions, a diagnosis of MCI 
is generally applied to individuals with a primary complaint 
and objective demonstration of cognitive impairments in 
one or more domains (usually memory difficulties), but with 
relatively preserved ADL.9,17 Debate continues regarding the 
most useful way to operationalize the clinical and research 
criteria for a diagnosis of MCI.18–24 Most MCI classifications 
require a subjective memory complaint, informant corrobora-
tion of memory difficulties, relatively intact ADL, and normal 
or mild problems in nonmemory cognitive functioning.9 More 
stringent classifications specify unique cutoff points for the 
severity of memory impairment on standardized neuropsy-
chological tests (eg, performance ,1.5 SD below the mean).25 
The clinical utility of MCI as a diagnostic classification is 
evidenced by estimates of increased risk for conversion to 
AD.24,26,27 While there are considerable individual differences 
in trajectories of change, in general, individuals with MCI 
progress to AD at a rate of 10% to 25% per year, compared 
with healthy elderly controls who progress at a rate of 
approximately 1% to 2% per year.9,18,24,28
Individuals with MCI tend to demonstrate impaired 
performance on neuropsychological tests of memory.9 This 
is in part a reflection of diagnostic criteria such that indi-
viduals with mild impairment in other cognitive domains 
may be missed. The pattern of memory decline observed 
in MCI appears to reflect a degradation of information in 
memory storage and retrieval, rather than an impairment of 
information encoding.25 The storage deficit is demonstrated 
in the loss of information over time, with minimal or no 
improvement in performance when assessed using tests 
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Figure 2 Global prevalence of Alzheimer’s disease as a function of age and total 
number of worldwide cases per year. 
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of recognition. This pattern of decline is generally consistent 
with that observed for individuals with AD, and is thought to 
be evidence that MCI is a preclinical stage of AD.
Recent research has revealed early changes associated 
with MCI including difficulties with executive functioning and 
increased apathy.9,29–31 Individuals with MCI have also been 
found to have difficulties dealing with financial matters, includ-
ing problems related to cash management and bill payment.32 
Given the overall high level of functioning, individuals with 
these difficulties tend to remain undetected, thereby making 
them more vulnerable for potential future decline.29,31 There-
fore, sensitive measures of memory, executive functioning, and 
personality shifts may help to improve prediction of conversion 
from MCI to more severe forms of dementia.9,29,31
Alzheimer’s disease
Risk factors
AD is the most common form of dementia, accounting for 
an estimated two-thirds of dementia cases in individuals 
aged 65 years or older.4,5 Age is the most consistent risk 
factor for AD, presumably due to lifelong exposure to 
various forms of neural damage, including minor vascu-
lar events, white matter disease, and inflammation.5,7,10,18 
Other potential risk factors include: level of education 
(higher education potentially conferring increased brain 
and cognitive reserve), gender (increased risk for female 
sex), family history of dementia (particularly for first 
degree relatives), genetic factors (familial forms of AD 
are associated with mutations in three autosomal domi-
nant genes: presenilin 1 (PS-1), presenilin 2 (PS-2), and 
amyloid precursor protein (APP), which are thought to 
work through increased production of Aβ peptides; and 
polymorphisms of apolipoprotein E, particularly Apoε4 
which is associated with 2 to 3 times (heterozygotes) and 
6 to 8 times (homozygotes) increased risk of develop-
ing AD), vascular risk factors (including hypertension, 
hypercholesterolemia, diabetes mellitus), mood disorders 
(particularly depression), and psychosocial lifestyle factors 
Depression, drug side effects,
metabolic disorders, vitamin B12
deficiency, infectious disease,
neoplasm, normal pressure
hydrocephalus, subdural hematoma
Gradual onset,
progressive decline, 
ADL impairments,
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Figure 3 Differential diagnostic considerations for dementia. 
Abbreviations: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; MCi, mild cognitive impairment; PDD, Parkinson’s disease 
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(including reduced intellectual, physical, recreational, and 
social engagement).7,33
Clinical features
AD presents with an insidious onset and progresses gradually 
and inexorably.34 Therefore, identifying specific time points 
corresponding to initial symptom onset is often difficult.28 
The diverse clinical features of cognitive impairment in AD 
reflect dysfunction of multiple regions of the cerebral cortex. 
Memory decline is commonly the   presenting complaint in 
AD, and represents a cardinal feature of the disease. The 
memory changes associated with AD are characterized 
as storage deficits, with rapid forgetting and poor delayed 
memory recall. In mild-AD, core episodic memory impair-
ments are observed, reflecting early medial temporal lobe 
and limbic involvement.8,35 For example, AD individuals may 
have difficulty recalling details of recent events, personal 
conversations, or specific elements of a task they may be 
performing (eg, preparing a meal). Often, they will ask the 
same question multiple times and may deny their repeated 
line of questioning.8 Individuals with AD also tend to con-
fabulate and generate inaccurate responses to questions.36 
On neuropsychological tests of word recall, AD patients 
produce more intrusions of incorrect word responses and 
inaccurately recognize words as being part of the original 
list (false positive responses) compared with individuals with 
other subtypes of   dementia.9 In general, deficits in declara-
tive memory (episodic memory) are prominent at the disease 
outset, with more severe memory impairments (semantic 
memory) emerging later in the disease course.35,37
Orientation to time and place are also disrupted early in 
the disease, probably because these abilities require effective 
learning and encoding of information from recent memory. 
As the disease progresses, orientation worsens to include 
problems identifying familiar places, family members, or 
other people well known to the individual.9
Procedural memory may also decline as the disease 
worsens, resulting in reduced ADL. Problems may include 
dressing or using common utensils and can be character-
ized as an ideomotor apraxia. On testing, these maladaptive 
behaviors are commonly seen when AD individuals use their 
finger as a toothbrush rather than pantomiming holding the 
toothbrush as requested.14
Language impairment, although generally preserved early 
in the disease, is also a prominent clinical feature. Initial signs 
of language dysfunction often include reduced expressive lan-
guage (conversational output), word-finding difficulties, and 
limited vocabulary. Category fluency (eg, naming animals or 
furniture) tends to be more impaired than semantic fluency 
(eg, naming words that begin with a particular letter), perhaps 
because category fluency is dependent on access to temporal-
lobe semantic stores.38,39 As the disease progresses, language 
difficulties become more pervasive and nonfluent. Spoken 
language may become less meaningful with an increase in 
comprehension difficulties, eventually resulting in global 
aphasia late in the course of illness.14
Although memory decline and language impairment are 
prominent findings in AD, involvement of other cognitive 
domains is also common. Visuospatial dysfunction may man-
ifest as impaired driving ability, getting lost, and difficulty 
producing drawings of figures. Problems with mathematical 
calculations may impair the individual’s ability to use money 
and balance their finances. Executive dysfunction results in 
deficits in problem solving, abstraction, reasoning, decision 
making, and judgment, particularly for novel situations. For 
example, AD individuals often display difficulty executing 
complex tasks, such as planning a vacation or negotiating a 
business deal.8
In addition to cognitive impairments, behavioral and 
psychiatric symptoms are common in AD. Depression rates 
vary by severity and disease stage, and can occur in up to 50% 
of AD individuals.40 Early in the disease course, depression 
may be attributed to awareness of the individual’s cogni-
tive changes. In the later stages, features related to apathy 
may present, but are often confused with depression, par-
ticularly by caregivers. Apathy is associated with significant 
caregiver distress and greater use of healthcare services in 
AD.41 Psychosis generally occurs later in the disease course. 
Delusions are predominantly paranoid in nature, with fears 
of personal harm or mistreatment, theft of personal property 
(usually related to financial matters), and marital infidelity. 
Hallucinations are less common than delusions, and tend to be 
visual. Other behavioral symptoms include agitation, wander-
ing, and sleep disturbances. The primary treatable behavioral 
and psychiatric symptoms in AD include psychosis, agitation, 
depression, anxiety, and insomnia.42
Diagnosis
The diagnosis of AD is based on identification and evalu-
ation of features of the individual’s history and clinical 
exam that are suggestive of the disease, while excluding 
other causes of dementia through the use of laboratory 
tests and neuroimaging. The two most commonly used 
diagnostic criteria for AD are those of the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition 
Revised (DSM-IV-TR),43 and those created by the National Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) joint task force (Table 1).44 
The DSM-IV-TR criteria require an insidious onset with 
progressive decline of cognitive function that results in 
impairment of social and occupational functioning, along 
with memory impairment and at least one other cognitive 
deficit that cannot be attributed to other psychiatric, neuro-
logical, or systemic disease. The NINCDS-ADRDA criteria 
classify AD according to three levels of diagnostic certainty: 
definite, probable, and   possible. A definite diagnosis of AD 
is restricted to individuals who meet the clinical criteria 
for probable AD and have corroborating neuropathological 
evidence of the disease (by biopsy or autopsy). Probable 
AD is the most definitive level of diagnostic certainty, 
without pathological confirmation. Probable AD requires 
a progressive decline of memory, along with at least one 
other cognitive domain that is confirmed through clinical 
examination and neuropsychological testing. The individual 
must have a preserved level of consciousness, with exclu-
sion of other conditions that may account for the symptoms. 
Additional features supportive of a probable AD diagnosis 
include: progressive decline of language functions, praxis, 
visual recognition, and impaired ADL, with normal results 
on laboratory tests (eg, cerebrospinal fluid examination), 
electroencephalogram, and neuroimaging. A diagnosis of 
possible AD is appropriate when the clinical course of cogni-
tive decline is atypical, when focal neurological findings are 
present, or when comorbid disorders exist that may account 
for the dementia-like symptoms. The NINCDS-ADRDA 
criteria are widely used for research and clinical diagno-
sis, and have been shown to have a predictive accuracy of 
up to 90%.35,45,46
vascular dementia
Risk factors
VaD is a clinical syndrome of acquired cognitive and 
functional impairments resulting from the effects of 
cerebrovascular disease. Due to the multiple etiologies of 
cerebrovascular disease, VaD can be characterized across 
a range of neurological and neuropsychological features 
that vary in presentation by onset (insidious or abrupt) or 
course (progressive, remitting, or static) of the dementia 
syndrome.47 Alternate definitions of VaD and a lack of 
universally accepted diagnostic criteria make it difficult to 
accurately estimate global prevalence rates. Nevertheless, 
general trends have been observed with prevalence estimates 
of 1% to 4% in individuals over 65 years, and worldwide 
prevalence rates of 15% to 22%.5,48 The association of stroke 
with cognitive impairment and vascular dementia has been 
demonstrated in a number of epidemiological, clinical, and 
neuropathologic studies.49–51 Comorbid disorders leading to 
hypoxemia (seizures, cardiac arrhythmia) have been shown 
to be potential risk factors for dementia in stroke patients.51 
Other clinical factors associated with a higher risk of VaD 
include increasing age, lower education, cortical atrophy, 
previous vascular events, and atherosclerosis.50,51 The asso-
ciation between hypertension and cognitive impairment 
remains a widely investigated area of research. Most longi-
tudinal studies have found a significant association between 
elevated blood pressure and the occurrence of dementia 10 to 
15 years later. In this association, diastolic pressure appears 
to be of greater importance than systolic pressure.52 A history 
of coronary artery disease, myocardial infarction, diabetes 
mellitus, smoking, and hyperlipidemia are additional risk 
factors for VaD.51–53 The underlying mechanism by which 
cerebrovascular risk factors lead to cognitive impairment 
Table 1 Summary of DSM-iv and National institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NiNCDS-ADRDA) criteria for the diagnosis of Alzheimer’s disease (AD)
DSM-IV criteria NINCDS-ADRDA criteria
•   Insidious onset with progressive decline of cognitive  
function resulting in impairment of social or occupational  
functioning from a previously higher level
•   impairment of recent memory and at least one of the  
following cognitive domains:
  – Aphasia
  – Apraxia
  – Agnosia
  –   executive functioning (planning, organizing, sequencing,  
abstraction)
• Probable AD
  – Deficits in two or more domains of cognition
  –   Progressive decline of memory and other cognitive functions
  – Preserved consciousness
  – Onset between ages 40 and 90 years
  –   Absence of systemic or other brain disease that could account 
for symptoms
• Possible AD
  – Atypical onset, presentation, or clinical course of dementia
  – Presence of another illness capable of producing dementia
•   Cognitive deficits are not due to other neurological, psychiatric,  
toxic, metabolic, or systemic diseases
• Cognitive deficits do not occur in the setting of a delirium
• Definite AD
  – Clinical criteria for probable AD
  – Tissue diagnosis by autopsy or biopsyJournal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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and dementia remains to be fully elucidated. Most studies 
suggest that cerebrovascular risk factors are associated 
with an increased prevalence of cerebral white matter 
abnormalities, whole brain atrophy, and silent stroke.54 
Associations have also been found between the extent of 
brain atrophy or white matter hyperintensity volumes and 
decreased cognitive abilities. Therefore, growing evidence 
suggests that cerebrovascular disease, even in the absence 
of clinical symptoms, may lead to subsequent cognitive 
impairment.55–57
Clinical features
Vascular dementia is a diagnostic classification used to 
describe a constellation of clinical features, including cogni-
tive and functional impairments.58 Three vascular syndromes 
are commonly cited in the literature: multi-infarct dementia, 
strategic single infarct dementia, and small vessel disease 
with dementia.
Multi-infarct dementia (also known as post-stroke 
dementia) is the most common form of vascular dementia.59 
It is attributable to multiple infarcts with occlusion, usually 
in large vessels, that cause cortical and subcortical infarcts. 
Occlusion of these arteries occurs as a result of atheroscle-
rotic thrombosis or cardiac embolization, and typically has 
an abrupt onset with stepwise progression. Multi-infarct 
dementia is characterized by variable impairment across 
several cognitive domains.60 Individuals may present with 
severe deficits in certain domains, while other cognitive 
abilities may be spared and remain relatively intact. With 
recurrent stroke episodes, greater areas of cognitive function-
ing become impaired and the dementia syndrome emerges. 
VaD individuals often present with lateralized sensorimotor 
changes, including hemiparesis, hemisensory loss, visual 
field disturbances, and pathological reflex asymmetries. 
Agnosia and apraxia may also be part of the clinical features 
in multi-infarct dementia.60
In strategic single infarct dementia, ischemic damage is 
focal and involves functionally important cortical and sub-
cortial regions including the thalamus, basal ganglia, angular 
gyrus, and frontal white matter.54 For example, an infarct in 
the angular gyrus may result in clinical features such as flu-
ent aphasia, alexia with agraphia, and spatial disorientation. 
Single lesions in the carotid, anterior, middle, and posterior 
cerebral arteries are known to give rise to clinical dementia 
symptoms with a number of neurological and neurobehav-
ioral features.51 Clinical evidence of stroke may or may not 
be present, but the onset of dementia is generally abrupt with 
a stepwise decline in cognitive functioning.
Small vessel disease with dementia refers to a syndrome 
in which occlusion of small vessels causes lesions of subcorti-
cal structures, including the thalamus, basal ganglia, internal 
capsule, and sub-hemispheric white matter. Disruption of 
these structures results in a form of subcortical dementia. This 
state is characterized by insidious onset of symptoms includ-
ing psychomotor slowing, memory impairments, changes in 
speed, and neuropsychiatric features such as depression and 
apathy. Neurological features include parkinsonism, ataxia, 
and urinary incontinence.61 Individuals with small vessel 
disease with dementia often present with slow, progressive, 
dementia-like features, often without clinical symptoms 
of stroke. Cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) 
is thought to be the hallmark disease associated with this 
clinical syndrome.62
Diagnosis
Several clinical criteria currently exist for the diagnosis of 
VaD dementia. The Hachinski Ischemic Scale (HIS) is a 
commonly used set of criteria for VaD that is easily applied 
in clinical practice.63 The HIS is based on 13 features used 
to obtain a total ischemic score. The current modified HIS 
emphasizes a subset of clinical symptoms as a means of 
distinguishing VaD from AD.64 The general features of the 
scale include: abrupt onset, prior history of stroke, focal 
neurological signs, focal neurological symptoms, stepwise 
deterioration, somatic complaints, emotional ability, and 
history of hypertension. Despite a sensitivity and specific-
ity of 70% to 80% in separating VaD from AD, the HIS is 
limited in its clinical use by not integrating neuroimaging 
information into the diagnostic process. The DSM-IV-TR 
approach utilizes clinical evidence of stroke-based signs 
from the neurological examination or neuroimaging evi-
dence for infarcts as the primary basis for a diagnosis 
of VaD.43 These criteria do not require that the dementia 
be temporally associated with the occurrence of stroke, 
which in effect decreases its specificity and clinical utility. 
Another definition of VaD is based on the World Health 
Organization’s International Statistical Classification of 
Diseases, 10th Revision (ICD-10), which requires a tem-
poral link between a stroke event and dementia, along with 
signs of stroke on neurological examination or imaging 
evidence of an infarct.65 A final diagnostic classification 
for VaD is based on the National Institute of Neurological 
Disorders and Stroke and Association Internationale pour 
la Neurosciences (NINDS-AIREN). These criteria are the 
most widely used for VaD in clinical trials research and Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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emphasize the heterogeneity of vascular syndromes and 
white matter lesions. The NINDS-AIREN criteria require 
neuroimaging evidence of lesions in key areas involved in 
VaD (frontal, temporal, or parietal cortex, thalamus, basal 
ganglia), along with critical abnormal white matter signals 
(.25% of total white matter volume).47
Frontotemporal dementia
The clinical and pathological understanding of frontotempo-
ral dementia (FTD) has undergone considerable changes in 
the past decade. Frontotemporal lobar degeneration (FTLD) 
is a descriptive term that encompasses a variety of clinical 
syndromes associated with nonAlzheimer pathology and 
arises from degeneration of the anterior hemispheres.66 
This heterogeneous group of clinical syndromes includes 
frontotemporal dementia (FTD), FTD with motor neuron 
disease (FTD/MND), progressive nonfluent aphasia (PNFA), 
semantic dementia (SD), and progressive apraxia.66 The 
most commonly occurring syndrome is frontotemporal 
dementia (FTD) which is characterized by profound altera-
tions in personality and behavior, and is associated with 
bilateral atrophy of the frontal and anterior temporal lobes.67 
Panels of expert international working groups have devel-
oped a number of clinical diagnostic criteria for FTD.67–69 
The   characteristic feature of FTD is a slowly progressive 
dementia that presents with either predominant behavioral 
or language disturbances (Table 2).70 FTD tends to have a 
younger age of onset than other dementias, typically between 
45 to 65 years, and approximately 20% to 30% of cases 
are familial and may be associated with mutations in the 
progranulin or MAPT gene.71 Prevalence studies of FTD 
are variable, with estimates ranging between 3.6 to 15.0 per 
100,000 individuals.72
Of the two FTD clinical presentations, the more common 
form is that of a behavioral disturbance, which is associated 
with profound changes in personality. Typical behavioral 
changes include apathy, lack of initiation, disinhibition 
(verbal, physical, and sexual disinhibition), perseveration, 
tactlessness, lack of social graces, emotional blunting, and 
loss of insight. FTD individuals tend to be unaware of or 
unconcerned about the social, occupational, and financial 
consequences of their behavioral changes.73 Cognitive deficits 
tend to occur in the domains of attention, abstraction, shift-
ing, planning and problem solving, reflecting an executive 
dysfunction.9
The less common presentation of FTD is that of a 
progressive and relatively isolated language disturbance. 
This language presentation can either be that of a difficulty 
with expression and naming, suggestive of a primary pro-
gressive aphasia (usually a nonfluent aphasia), or that of 
difficulty with word meaning, consistent with a semantic 
dementia.68 Progressive nonfluent aphasia presents with a 
gradual disturbance of expressive language with effortful 
speech production, phonological and grammatical errors, 
and word retrieval difficulties, ultimately followed by 
later mutism. Reading and writing can also be impaired. 
Other cognitive functions are usually spared and these 
individuals have relatively preserved social skills early in 
the disease.9 Semantic dementia presents with progressive 
impairment of comprehension of words and naming in 
the context of fluent, effortless and grammatically correct 
speech output. Memory functions are relatively preserved, 
along with word repetition, reading skills, and mathemati-
cal abilities.9
The different clinical presentations of FTD are thought to 
be associated with the initial focal pattern of cortical atrophy 
of the frontal lobes. However, as the disease progresses a 
more global pattern of cognitive impairment emerges.68 On 
examination, early signs include the presence of a grasp, 
snout, or palmomental reflex. Further, disinhibition and 
perseverative behaviors are often observed. The presence of 
additional neurologic abnormalities may suggest early motor 
neuron disease (MND) or parkinsonism. There are no widely 
accepted bedside cognitive or behavioral tests for FTD, and 
measures of global cognition like the Mini-Mental State 
Examination (MMSE) are insensitive to change in behavior, 
Table 2 Common clinical presentations of frontotemporal dementia
Presentation Clinical features
Behavioral •   impulsive behaviors and disinhibition  
(eg, inappropriate sexual behaviors)
•   Change in personality (eg, indifference, apathy,  
mental inflexibility)
•   Poor judgment and poor insight into consequences  
of behaviors (eg, financial risk taking)
•   Repetitive, compulsive, stereotypic behaviors  
(eg, hyperorality)
•   Loss of personal hygiene (eg, wearing same clothes  
for multiple consecutive days
•   Loss of social graces/insight (eg, making jokes during   
a funeral)
Language •   Non-fluent aphasia → with anomia, agrammatism,  
phoemic paraphrasias, impaired word repetition,  
alexia, agraphia
•   Fluent-aphasia → with early loss of word meaning  
(ie, empty speech), poor comprehension, semantic  
paraphrasias, prosopagnosia, associative agnosia
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aphasia detection, and evaluation of executive function. 
If FTD is suspected, a more extensive neuropsychological 
battery should be administered and the individual should be 
monitored closely.
Dementia with Lewy bodies
Dementia with Lewy bodies (DLB) usually presents in 
older adulthood between the ages of 60 and 90 years. The 
epidemiology of DLB remains to be fully elucidated along 
with potential risk factors for the disease, but to date no 
significant gender or ethnic differences in prevalence have 
been identified.74 DLB is a neurodegenerative disorder, thus 
progressive and functionally disabling cognitive impair-
ment is a central feature. Individuals with DLB exhibit a 
combination of cortical and subcortical impairments with 
significant attentional deficits and executive and visuospa-
tial dysfunction.9 Compared to AD, there may be relative 
sparing of memory functions especially in the early stages 
of DLB.75 A recent international consortium has resulted 
in revised criteria for the clinical diagnosis of DLB, incor-
porating new information about the core clinical features 
of the disease. These core features include fluctuating 
cognition, recurrent visual hallucinations, and spontaneous 
parkinsonism.76
Fluctuations in cognitive function with pronounced varia-
tions in attention and alertness can be difficult to evaluate 
and operationalize, but corroborative reports from primary 
caregivers can help to clarify these essential clinical features 
(eg, daytime drowsiness, prolonged staring spells, periods of 
marked confusion, disorganized speech).76 Cognitive fluctua-
tions are reported across varying time periods, but generally 
take place for a minimum of 30 minutes and can last as long 
as several days.9
Visual hallucinations in DLB tend to be recurrent, vivid, 
and well-formed. The hallucinations tend to emerge early 
in the disease course, and are therefore a useful diagnostic 
feature. The content of the hallucinations usually consist of 
humans or animals, but can be more abstract in nature. Visual 
illusions and delusions, which typically have a paranoid 
quality, are also commonly observed. Auditory, tactile, or 
olfactory hallucinations are rare. Functional neuroimaging 
studies have demonstrated altered patterns of activation in the 
visual cortex, along with increased number of Lewy bodies 
in the anterior and medial temporal lobe of individuals with 
DLB who report hallucinations.77 Other common neurop-
sychiatric features include depression, apathy, and anxiety. 
Agitation and aggressive behavior tend to occur late in the 
course of the disease.
Extrapyramidal signs, including bradykinesia, facial 
masking, and rigidity, are the most frequent signs of par-
kinsonism in DLB. Resting tremor is distinctly uncommon, 
and parkinsonism is usually bilateral and occurs with the 
onset of dementia. There is often more axial rigidity and 
facial masking in DLB than is typically seen in idiopathic 
Parkinson’s disease.76
An important suggestive clinical feature of DLB includes 
rapid eye movement (REM) sleep behavioral disturbances. 
Affected individuals often act out their dreams by scream-
ing and kicking, which can cause injuries to themselves 
and those around them. The dreams tend to have a chasing 
or attacking theme, and their content usually matches the 
exhibited behavior. REM sleep behavior disturbances often 
begin years before the onset of other cognitive or motor 
symptoms.78
Other suggestive features of DLB include severe neuro-
leptic sensitivity, and low dopamine transporter uptake in 
the basal ganglia on functional neuroimaging. Additional 
supportive features that commonly occur in DLB include 
repeated falls and syncope, transient, unexplained loss of 
consciousness, severe autonomic dysfunction, hallucinations 
in other modalities, systematized delusions, relative preserva-
tion of medial temporal lobe structures on structural neuroim-
aging, reduced occipital activity on functional neuroimaging, 
prominent slow wave activity on electroencephalogram, and 
low uptake myocardial scintigraphy.76
Multidisciplinary team approach  
to dementia care
An integrated multidisciplinary approach to diagnosing and 
managing dementia is highly recommended in clinical prac-
tice because no single healthcare specialty has the expertise 
to deal with the complex range of cognitive, physical, social, 
and emotional problems associated with dementia. Manag-
ing dementia presents unique challenges to the practicing 
clinician, and effective care hinges on a collaborative team 
approach. This approach relies less on standard pharmaco-
logically based medical practice, and more on the integration 
of therapies from a wide range of healthcare providers and 
community professionals. To implement this approach effec-
tively, the clinician must understand the disease processes 
involved and the clinical presentation of dementia, and also 
appreciate the caregiving experience and how it affects patient 
care. The clinician must be informed about the resources 
available to meet the medical, social, and emotional needs 
of the patient in the context of their family and community. 
Using a multidisciplinary team approach can be complex, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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but it benefits both the patient and the clinician. It allows 
clinicians to focus on the issues most relevant to their area of 
expertise, and it facilitates management of patient problems 
that are likely to require valuable healthcare resources.15
Multidisciplinary team structure
The best approach to the care of individuals affected by 
dementia includes support from multiple sources. These may 
be integrated, parallel, or a combination of both. It is ideal for 
patients and caregivers to seek a blend of multidisciplinary 
services that come from various healthcare providers, social 
service agencies, and professionals from outside the field of 
healthcare. Multidisciplinary teams vary in their composition 
and may be structured either formally or informally. Team 
construction is usually dictated by resources, including time, 
availability, finances, and geographic location. Regardless 
of structure, successful teams are characterized by a shared 
commitment to quality care and an appreciation for the 
contributions of each team member.79,80
Multidisciplinary teams involved in dementia care tend to 
be based primarily on the availability of service resources, in 
addition to the social and cultural context of the community. 
Team members often include neurologists, geriatricians, neu-
ropsychologists, nurse practitioners, physical/occupational 
therapists, nutritionists, and social workers.15
The neurologist or geriatrician’s primary responsibility is 
the diagnosis of dementia using validated criteria and practice 
guidelines. Following diagnosis, a prognosis is determined 
and a treatment plan is formulated to address the disease and 
underlying symptoms.15 When diagnostic uncertainty exists, 
referral to a subspecialist may be useful to refine the diagno-
sis and help develop a plan of care. Dementia subspecialists 
may include behavioral neurologists, geriatric psychiatrists, 
or neuropsychologists. The role of a neuropsychologist is to 
interpret quantitative cognitive performance data based on 
the results of psychometric testing. Many neuropsychologists 
also provide ongoing therapy and support to the dementia 
patient, and their family members.9
The nurse’s primary role is to assess and manage the 
dementia patient and their caregivers’ responses to the disease 
process. This includes monitoring symptom presentation, 
responding to medication issues, providing education and 
relevant information to family members, and assisting them 
in preparing for disease progression. Dementia frequently 
results in immobility, decreased physical conditioning, loss 
of muscle strength and tone, and poor coordination. Impaired 
ambulation is common and increases the risk of falls and 
injury. Physical therapists can assist dementia patients 
to optimize their physical conditioning and maintain safe 
mobility, helping to prolong independent living and the need 
for institutionalization.81
Another important factor in maintaining the dementia 
patient’s home independence is their ability to manage ADL. 
Occupational therapists help the patient and their caregiv-
ers to adapt to the patient’s diminished ability to deal with 
challenges faced in daily living. Use of devices to assist with 
toileting, eating, dressing, and home management can be 
recommended and demonstrated by an occupational thera-
pist. As patient independence is enhanced, caregiver burden 
decreases.82 Cognitive impairment related to dementia also 
places the patient at increased risk for malnutrition and dehy-
dration. In later, more severe stages of dementia, the patient 
often experiences sensory-motor impairments with ensuing 
loss of ability to swallow or eat independently. Weight loss 
then becomes a significant concern as the disease progresses. 
Comorbid conditions common to older individuals such 
as diabetes and coronary heart disease also make dietary 
management more challenging. Dietary intake also extends 
beyond medical concerns, and becomes an important quality 
of life consideration.83
Social workers base their practice on the philosophy 
that the individual is part of a larger system, and they are 
prepared to assist the patient and their family in identifying 
and   acquiring the resources needed to manage the burden of 
chronic illness.84 In nearly all cases, patients with dementia 
and their caregivers will require access to social services 
including community programming, respite care, financial 
services, counseling support groups, and crisis manage-
ment. Therefore, it is often recommended that a referral to a 
social worker be initiated at the time of formal diagnosis of 
dementia.15 As the disease progresses, increasing levels of 
support will be required. The social worker is able to help 
anticipate future needs, facilitate the acquisition of services, 
and navigate the patient and their caregivers through the 
extended healthcare system. For individuals with dementia, 
the home environment has been found to promote a sense 
of personhood, normalcy and continuity in the face of dis-
connection that is often experienced as a result of multiple 
losses in functional, cognitive, and social domains of their 
lives.85 Consequently, ‘aging in place’ is considered to be 
the preferred choice for many older adults to help maintain 
independence.86,87   However, individuals with dementia often 
require care within a structured, institutionalized environ-
ment. Caregivers’ reasons for placement into institutional-
ized care are diverse and often include: 1) the need for more 
skilled care and more assistance, 2) the caregivers’ health, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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3) the presence of behavioral and psychological symptoms 
of dementia, 4) caregiver burden, and 5) use of community-
based services.88 Given the practical and emotional chal-
lenges involved in transitioning from a home environment to 
an institutionalized care facility, the social worker can help 
guide the dementia patient and their family members through 
this difficult process.
Managing and treating dementia
Current clinical practice encourages open discussion of the 
diagnosis of dementia with patients and their caregivers to 
facilitate early implementation of treatment strategies, and to 
allow families to plan for the future. An integrated approach 
involving both pharmacological and psychosocial strategies 
is essential for effective care and management. This approach 
often includes community support services, professional 
groups and associations, specialized dementia clinics, and 
geriatric outreach services.
Pharmacologic treatment of dementia
Two classes of drugs are currently approved for the symp-
tomatic treatment of dementia: acetylcholinesterase inhibitors 
(AChEI) and N-methyl-D-aspartic acid (NMDA) receptor 
antagonists (Table 3). These pharmacologic treatments do 
not target the underlying pathogenesis of dementia, but rather 
help to improve or maintain function following neuronal 
damage.89
The development of AChEIs emerged from a pathophysi-
ologic model of AD known as the amyloid cascade 
  hypothesis. In this model, it is proposed that accumula-
tion of Aβ in the brain is the primary force driving AD 
pathogenesis, with the rest of the disease process resulting 
from an imbalance between Aβ production and clearance. 
Within the cascade, a dysregulation in amyloid precursor 
protein (APP) processing by β- and γ-secretases initiates 
the pathogenic events leading to aggregation of Aβ, specifi-
cally Aβ42, an insoluble fragment that deposits in plaques. 
The formation of these amyloid plaques further instigates 
pathological events, including the formation of neurofibril-
lary tangles (NFTs) from hyperphosphorylation of the tau 
protein, disruption of synaptic connections, reduction in 
neurotransmitters, death of tangle-bearing neurons, harm-
ful oxidative processes, damaging inflammatory responses, 
and the eventual emergence of the clinical symptoms of 
  dementia.90 Although the amyloid cascade hypothesis has 
gained wide acceptance in the field of dementia research, it 
remains   controversial. Emerging evidence shows that many 
other neuropathological processes may be involved, including 
the theory that the central mechanism is the hyperphospho-
rylation of the tau protein. More recent data from multidis-
ciplinary research has suggested the importance of vascular 
risk factors (eg, smoking, obesity, hypercholesterolemia) 
and vascular morbidity (eg, hypertension, diabetes, silent 
brain infarcts, and white matter lesions) in the pathology of 
dementia.5,91,92
Pharmacotherapy for AD
There are four currently approved AChEIs for the treatment 
of AD: tacrine, donepezil, rivastigmine, and galantamine. All 
of these drugs are approved for mild to moderate AD, with 
the exception of donepezil, which is approved for mild to 
severe AD.89 Head-to-head clinic trials comparing the effec-
tiveness of each of the AChEIs are rare, thus making it dif-
ficult to determine which is best for the treatment of patients 
with AD. Tacrine has an inconvenient dosing schedule (four 
doses daily), and significant side effects (hepatotoxicity), 
and is rarely used in current clinical practice.91 The other 
three AChEIs appear to be relatively equivalent in terms of 
efficacy and are associated with symptomatic improvement 
in cognitive function in patients with mild to moderate AD. 
Improvement generally lasts for 6 to 12 months, followed by 
a gradual decline in most, but not all, cases.89
There is some controversy on the duration of use of 
AChEIs in the treatment of patients with AD. Some clinicians 
feel that once a patient has reached the stage of severe AD, 
AChEI use should be discontinued. Others feel that AChEIs 
may still be useful for managing symptoms in severe AD, but 
this remains an active and open area of clinical investigation. 
Despite this controversy, AChEIs represent the primary form 
of treatment for AD.
Memantine is currently the only NMDA antagonist 
approved to treat AD. The rationale behind the use of 
Table 3 Pharmacologic treatments for dementia
Drug name Mechanism Daily  
dosage
Side effects
Donepezil AChe inhibitor 5–10 mg Nausea, vomiting,  
diarrhea, vivid  
dreams, leg cramps
Rivastigmine AChe inhibitor 3–12 mg Nausea, vomiting,  
diarrhea, weight  
loss, anorexia
Galantamine AChe inhibitor 8–12 mg Nausea, vomiting,  
diarrhea, weight  
loss, anorexia
Memantine NMDA receptor  
antagonist
10–20 mg Hallucinations,  
confusion
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memantine is the glutamatergic excitotoxicity theory, which 
stipulates that an abnormal and sustained increase in glutamate 
may lead to neuronal degeneration. Memantine, an NMDA 
receptor, is a low-to-moderate uncompetitive antagonist that 
blocks glutamate binding to its receptor, thereby decreasing 
neuronal excitotoxicity and slowing the progression of AD.93 
Memantine has been approved for the treatment of all stages 
of AD, but in clinical practice is generally used in moderate-
to-severe AD. Administered twice daily, compliance is a 
common issue with memantine, as it is difficult for patients 
with AD to maintain their dosage schedule. Memantine is a 
symptomatic treatment for AD, and has been shown to improve 
cognitive function and slow the rate of decline in moderate-
to-severe cases. The duration and extent of cognitive efficacy 
is approximately 6 months, and may be   greater.94 Additional 
studies are needed to determine whether the efficacy of 
memantine in patients with moderate-to-severe AD extends 
beyond 6 months.
Pharmacotherapy for non-AD dementias
Vascular dementia can be treated by the use of donepezil, 
rivastigmine, and galantamine in patients with probable and 
possible VaD.47 Several clinical trials have shown that anti-
hypertensive therapy can help to prevent the onset of VaD 
in certain individuals.95
DLB is a form of dementia that is not easily treated 
through the use of pharmacotherapy. Rivastigmine has shown 
some improvement in DLB patients, and low-dose clonaze-
pam has been used for sleep disturbances. Psychostimulants, 
including levodopa and dopamine agonists, have been shown 
to improve cognition, apathy, and psychomotor slowing. 
Management of cognitive fluctuations in DLB has been 
  difficult. Atypical neuroleptics have also been reported to be 
helpful for symptoms of delusions and agitation, and selective 
serotonin reuptake inhibitors (SSRIs) can be effective for the 
treatment of depression and anxiety in DLB patients.96
Frontotemporal dementia is another challenging form of 
the disease where management and treatment strategies have 
been inconsistent and disappointing to date. Few large-scale, 
clinical trials for the treatment of FTD have been conducted, 
although several smaller trials have been carried out. In these 
studies, rivastigmine and SSRIs have been shown to improve 
behavioral symptoms of FTD, but cognitive improvement 
has been limited.97,98
Goals of pharmacotherapy for dementia
At the initiation of pharmacologic treatment for dementia, 
the goals of therapy should be clearly established with the 
patient and their caregivers. AChEIs and memantine are not 
as effective as drug medications for other medical conditions, 
and it is important to clarify that they do not alter the eventual 
course of the disease. The treatment options available mainly 
stabilize the patient, delaying subsequent decline, with some 
individuals experiencing transient symptomatic improve-
ments. Clinicians must set realistic goals that take into account 
the modest benefits that can be expected in various cognitive, 
behavioral, emotional, and functional domains.
Nonpharmacologic treatment  
of dementia
Over the past 3 decades, interest has grown in the use of non-
pharmacologic treatment approaches, alone or in combination 
with pharmacotherapy, for the treatment and management of 
dementia. Several therapies have been suggested including 
cognitive-based therapies, psychosocial therapies, physical 
therapies, and sensorial therapies. These strategies may be 
implemented in a variety of settings (home, institutional 
care facility) and treatment modalities (individual or group-
based therapy). The clinical efficacy of nonpharmacologic 
treatments remains to be fully evaluated, but it is understood 
that the primary goal of these approaches is to improve the 
quality of life for individuals with dementia.
Cognitive-based interventions
Cognitive interventions for dementia rely on the plasticity 
hypothesis, which theorizes that the brain is able to achieve 
neural and functional improvements by reorganizing its con-
stituent elements and internal network connectivity according 
to environmental constraints.99
Cognitive training and cognitive rehabilitation are the 
two most commonly applied nonpharmacologic   strategies to 
implement in the early stages of dementia. These   interventions 
involve targeted practice and training of specific cognitive 
domains, with a primary emphasis on memory, attention, 
and executive functions. Cognitive rehabilitation differs from 
cognitive training in that it is a more individualized thera-
peutic approach, and its goals are to enhance functioning in 
everyday life, rather than improve performance on cognitive 
tasks. A recent Cochrane review examined the efficacy of 
cognitive training and rehabilitation in patients with early 
stage AD and VaD in five domains from nine randomized 
controlled trials including participant scores on cognitive 
screening measures, neuropsychological tests, self-reported 
functioning, informant ratings of functioning, and reac-
tions to memory impairments and behavioral difficulties. 
While some positive results were found in specific cognitive Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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domains, overall improvements were limited and there were 
no significant differences between cognitive training and 
control groups.100
Psychosocial therapies
Psychosocial therapy is an intervention that is intended to 
enhance self-esteem, well-being, social and communication 
skills, and to decrease behavioral disturbances.
Reminiscence therapy is a common psychosocial inter-
vention in dementia care. Initially introduced in the 1980s, 
this approach is based on evocation and discussion between 
the dementia patient and trusted individuals to think about 
and revisit past events, experiences, and activities. It often 
involves the use of objects and supports (eg, photos, personal 
belongings, music) to help trigger specific memories. Very 
few randomized controlled trials have assessed reminiscence 
strategies in dementia. A recent Cochrane meta-analysis 
concluded that reminiscence therapy resulted in significant 
improvements in behavioral functioning, as well as cognitive 
and depressive symptoms, compared with no-treatment and 
social-contact control groups, with sustained effects 4 to 6 
weeks after cessation of the intervention.101
Validation therapy is another form of psychosocial inter-
vention for the treatment of dementia. The goal of validation 
therapy is to promote and stimulate communication skills 
in the dementia patient, and to provide the individual with 
insight into their external reality. A recent Cochrane review 
found little evidence supporting this form of intervention, 
but noted that the limited information from randomized 
controlled trials is insufficient to draw reliable conclusions 
about the efficacy of validation therapy in dementia.102
Physical activity therapy
Physical activity can be used as a therapeutic approach in 
a wide range of target populations including healthy aging 
adults and individuals with dementia. The benefits of physical 
activity have been demonstrated in terms of mood, quality of 
life, falls, cardiovascular function, and disability rates.103–106 
Regular exercise can also slow down or help prevent func-
tional decline associated with aging, improve muscle mass, 
arterial compliance, energy metabolism, cardiovascular 
  fitness, and overall functional capacity.107
An individual’s overall physical fitness is composed of 
several components including cardiorespiratory and muscular 
fitness, flexibility, and balance. Cardiorespiratory fitness, 
also known as aerobic training, is a condition in which the 
cardiovascular and respiratory systems function together to 
ensure that adequate oxygen is supplied to working muscles 
to produce energy. A high level of cardiorespiratory fitness 
permits continuous physical activity without a decline in 
performance and allows for rapid recovery. It is also believed 
that cardiovascular fitness can improve cognitive   capacities. 
Animal research has demonstrated beneficial effects of 
aerobic physical activity on cognition, through physiological 
processes involved in increased cerebral blood flow, oxygen 
extraction, and glucose utilization.108 It has therefore been 
suggested that physical activity may act as a protective factor 
for cognitive decline in older adults.109
A recent Cochrane review examined the effects of physi-
cal activity (aerobic exercise training or physical activity of 
any length of time) on cognition, function, and behavior in 
individuals with dementia. The review also evaluated care-
giver outcomes and healthcare service use. No significant 
results were observed but numerous methodological factors 
limited the potential findings of the meta-analysis.110 More 
studies with homogeneous populations, in terms of demen-
tia subtype and severity, are required to fully investigate 
the role of physical activity in dementia. Moreover, several 
key questions about physical activity remain to be clarified, 
including how long the effects of exercise last after cessa-
tion of training, and how much exercise is required to exert 
a beneficial effect.
Managing and treating BPSD
BPSD occur in individuals with any of the dementia subtypes 
and include a heterogeneous range of psychological reactions, 
psychiatric symptoms, and behavioral disturbances. BPSD 
can cause serious complications often leading to increased 
emergency department visits, caregiver distress and illness, 
increased financial costs to society, early institutionalization, 
and diminished quality of life.12,13,81,111,112 Therefore, effective 
management of BPSD in dementia is an important treatment 
consideration.
BPSD can generally be separated into behavioral excesses, 
wherein the occurrence of the behavior is problematic (eg, 
physical and verbal aggression, agitation, anxiety, disinhibi-
tion, depression, aberrant motor behavior, irritability, hal-
lucinations, and delusions) and behavior deficits, wherein 
the nonoccurrence of the behavior causes the complications 
and challenges (eg, apathy leading to withdrawal from 
social interactions, cessation of self-care including eating 
and dressing, and sleep disturbances (Table 4).11,113,114 The 
most frequently occurring BPSD are apathy, depression, and 
anxiety.115,116 BPSD can occur at any stage along the demen-
tia continuum, but certain symptoms have been found to be 
more common in mild dementia (eg, depression, anxiety, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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irritability, and apathy), while others occur more frequently in 
later stages of the disease process (eg, aberrant vocalizations, 
delusions, hallucinations, and disinhibition).117–119 Agitation 
and aggression are among the most challenging BPSD for 
caregivers, and along with psychosis and depression are the 
leading predictors of institutionalization.120 When present, 
inappropriate sexual behaviors have been rated by caregivers 
as the most difficult symptom of BPSD to manage.121,122
A variety of biological, psychosocial, and environmental 
factors have been proposed to explain the development of 
BPSD. Psychosocial models of BPSD include: Need-Driven 
Dementia Compromised Model, Progressively Lowered 
Stress Threshold Model, and the Biopsychosocial Model 
of Dementia.
Need-Driven Dementia Compromised Model
Within the context of the Need-Driven Dementia Compro-
mised Model, BPSD is considered to be the most integrated 
and meaningful response possible by an individual with 
dementia to their environment.123 According to Algase, BPSD 
arise due to the pursuit of a goal or as an expression of a 
need by the individual with dementia. It is also suggested 
that the presence, severity, and type of BPSD is a reflection 
of the interaction between salient background factors which 
are somewhat stable individual characteristics (eg, gender, 
personality type, general health), and proximal factors 
which are more fluid or fluctuating aspects of the immedi-
ate physical and social environment, as well as the dynamic 
or changing needs and internal states of the person with 
dementia (eg, temperature, excessive noise, hunger, fear). 
Seen this way, the Need-Driven Dementia Compromised 
Model defines BPSD as meaningful and potentially useful 
behaviors that can direct and inform appropriate caregiver 
responses. The primary goal is therefore not to eliminate 
the behaviors completely, but rather to understand them and 
enable caregivers to more readily and accurately meet the 
needs of the person with dementia.123
Progressively Lowered Stress Threshold Model
The Progressively Lowered Stress Threshold Model posits that 
persons with dementia are increasingly less able to manage 
stress as the disease progresses.124 This reduction in their capac-
ity to tolerate stress results in anxious behaviors as an attempt 
to alleviate perceived stress. According to Hall and Buckwalter, 
BPSD (referred to as catastrophic reactions) occur if the stress 
is unrelieved through either adaptation of the environment or 
appropriate responses from caregivers or both.124
Biopsychosocial model of dementia
The biopsychosocial model of dementia is a theoretical frame-
work developed to illustrate the role of psychosocial factors 
within the context of biological processes and to increase 
understanding of the factors that may lead to improvement 
or deterioration in dementia.125 This model suggests that in 
both biological and psychosocial domains there are fixed 
factors, which are not amenable to change (eg, age, educa-
tion, gender, personality traits), and tractable factors, which 
are more flexible and adaptive (eg, pain, physical and social 
environment, level of physical and social activity). The tra-
jectory of dementia is presented as a process, beginning with 
aging, early organic change, initial cognitive impairments, 
formal diagnosis of dementia, and then moves progressively 
towards dependency, institutionalization, end of life care, 
and eventual death. In the biopsychosocial model, the fixed 
and the tractable factors will simultaneously influence the 
point at which the symptoms of dementia begin, the nature 
and speed of the deterioration, and the effectiveness and 
appropriateness of interventions used by caregivers to assist 
persons with dementia. The primary aim of this model is to 
increase caregivers’ ability to identify ways to improve the 
quality of life and reduce excess disability (often by reducing 
BPSD) for the person with dementia.125
environmental factors
Environmental factors that have been found to contribute to 
the development of BPSD can be divided into two subgroups: 
the physical environment (eg, architectural features, interior 
design features, and sensory attributes such as lighting and 
noise levels) and the social environment (eg, optimizing the 
mix of residents, social stimulation, and sensory   stimulation). 
Physical environmental factors that are precursors to 
BPSD include inadequate lighting, confusing surroundings, 
Table 4 Neuropsychiatric features of behavioral and psychological 
symptoms of dementia
Presentation Clinical features
Behavioral and  
psychological excess
Aggression: aggressive resistance, verbal  
or physical aggression
Agitation: aimless walking, pacing, trailing, 
restlessness, repetitive actions, sleep  
disturbances
Psychosis: hallucinations, delusions,  
misidentification
Behavioral and  
psychological deficits
Depression: sad, tearful, hopeless, low  
self-esteem, anxiety, guilt
Apathy: withdrawal, lack of motivation,  
loss of interestJournal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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excessive noise/stimulation, and poorly designed care 
environments.120,126 Social environmental factors that have 
been found to contribute to the presence of BPSD include 
a lack of daily routine, excessive demands from caregivers, 
distressing behavior of others, loneliness/boredom, and 
social isolation.120
Person-centered care for BPSD
Many management and treatment interventions for BPSD 
are underpinned by a person-centered care approach. An 
important aspect of the person-centered approach is the 
therapeutic benefit of positive interpersonal interactions. 
The conditions that influence positive change include 
having a therapist who provides unconditional positive 
regard, is empathetic, and is genuine or congruent within 
the client–therapist relationship.127 This person-centered 
approach has been adopted and applied to dementia indi-
viduals in long-term care settings.128 It involves recogniz-
ing and identifying the personal preferences and needs 
of dementia patients as a way to guide caregiving, thus 
enabling the individualization of care plans and routines. 
Additionally, a central feature of person-centered care is 
the recognition that all human life is grounded in relation-
ships, and that individuals with dementia need an enriched 
social environment that fosters opportunities for personal 
growth while compensating for their cognitive and func-
tional impairments.128,129
The key elements of person-centered care include 1) 
knowing the person as an individual; 2) providing care that 
is meaningful to the person in ways that respect their values, 
preferences, and needs; 3) viewing patients as biopsychoso-
cial beings; 4) enabling the development of consistent and 
trusting caregiving relationships; 5) emphasizing freedom 
of choice and individually defined risk taking; 6) promoting 
emotional and physical comfort; and 7) involving patients’ 
family, friends, and social networks in care decisions.129
Findings from empirical studies demonstrate that the 
application of person-centered care results in reduced 
neuroleptic medication use and agitation.130,131 Despite the 
widespread recognition and application of person-centered 
care for individuals with dementia, many studies to date 
are conceptual or anecdotal, highlighting the need for more 
research on this treatment approach.132
Nonpharmacological treatments for BPSD
Nonpharmacological treatments for BPSD can be grouped 
into two categories: 1) indirect interventions aimed at 
decreasing BPSD through indirect work with caregivers or 
the environment, and 2) direct interventions targeted directly 
at individuals to decrease BPSD.
indirect interventions
Caregiver training
The aim of caregiver training is to increase formal and infor-
mal caregiver understanding of BPSD, and improve skills in 
managing and responding to problem behaviors. Education 
and training programs have been found to be effective in 
the reduction of BPSD in both nursing home environments, 
and the community.133,134 Multidisciplinary team approaches 
and individualized treatment plans developed according to 
the unique needs of the individual with dementia, combined 
with caregiver problem-solving techniques are key features 
of successful education and training interventions.135,136
environmental adaptations
When BPSD appear to be triggered by environmental factors, 
interventions aimed at modifying the individual’s environ-
ment may be the most effective means to address the behav-
iors. Key environmental features include: 1) architectural 
elements, such as room layout and size (eg, smaller social 
spaces); 2) interior design features, such as furniture type 
and arrangement (eg, homelike furnishing, familiar objects, 
and personalized rooms); and 3) sensory attributes (eg, noise, 
lighting, and visual accessibility). Adaptations of these 
environmental features have been found to reduce anxiety, 
increase a sense of emotional well-being, and enhance social 
interaction for individuals with dementia.126,132,137–139
Direct interventions
Sensory therapy
Various sensory-based therapies have been developed for use 
with dementia populations, including music therapy, light 
therapy, and Snoezelen therapy. Music therapy is defined as 
the use of music or musical elements (voice, sound, rhythm) 
by a qualified music therapist. This   nonpharmacologic 
approach is believed to promote nonverbal communication, 
relationships, learning, expression, and to improve emotional, 
social, and cognitive functioning through increased quality of 
life. Music therapy can be applied on an individual or group 
level, and may be active or receptive. Several randomized con-
trolled trials of music therapy in dementia have recently been 
conducted, and significant positive effects have been found 
in the reduction of BPSD. Specific improvements were found 
on indices of anxiety and depression for up to 8 weeks after 
discontinuation of music therapy.140–142 Background music has 
also been shown to be effective in reducing agitation.143,144Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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The complexity of BPSD in dementia suggests that 
a multi-factorial and integrated approach is required for 
appropriate intervention and management. Approaches 
that do not take into consideration the complex biological, 
psychosocial, psychological, and environmental factors will 
likely produce results that are sporadic, inconsistent and 
short lived. Consequently, a comprehensive and integrated 
approach, which addresses the needs of the individual with 
dementia, the caregivers, and the physical and psychosocial 
environment is highly recommended.
Empirical research on dementia: 
toward facilitating early detection 
of those at risk
Considerable effort has been devoted to better understand-
ing change in cognitive functioning during the prodromal 
phase of dementia.145 This research focus is well intentioned 
given the protracted nature of neuropathological change 
in dementia, coupled with the fact that effective treatment 
pharmacotherapy remains elusive.146 Ultimately, the success 
of potential interventions will be further augmented through 
the early detection of those at risk. In this spirit, we briefly 
summarize some recent empirical findings of preclinical 
cognitive deficits in AD, and discuss some potentially fruitful 
avenues for future research.
Characterizing cognitive decline during 
the prodromal phase of dementia
A recent meta-analysis examined 47 studies comprising 
more than 1200 AD cases and 9000 controls.147 Among the 
primary foci, the meta-analysis examined preclinical AD 
impairment across multiple cognitive domains, as well as the 
moderating impact of the length of the prodromal period on 
the magnitude of the preclinical AD effect. Consistent with 
expectation, larger prodromal deficits were observed for 
studies characterized by a time interval of less than 3 years 
between cognitive assessment and clinical diagnosis, rela-
tive to studies with average follow-up periods greater than 
3 years. For example, episodic memory differences between 
cases and controls were characterized by a large effect (1.12 
SD units) within 3 years of diagnosis, but a moderate effect 
(0.76 units) for studies with follow-up intervals greater 
than 3 years between testing and diagnosis. Another criti-
cal finding from the meta-analysis concerned the pattern of 
deficits as a function of cognitive domain. Consistent with 
the etiology of AD, large magnitude deficits in episodic 
memory were observed for AD cases relative to controls. 
Large-magnitude cognitive deficits were also observed, 
however, for measures of executive functioning, process-
ing speed, and global cognition, consistent with the notion 
that deficits in multiple cognitive domains characterize the 
prodromal phase of dementia.
On the surface, detecting such large-magnitude deficits 
would represent seemingly positive news vis-à-vis early 
detection of those at risk of dementia. However, despite 
the large magnitude differences in mean performance 
across multiple cognitive outcomes, considerable overlap 
(.40%) remained across performance distributions for the 
preclinical AD vs nondemented groups, with this overlap 
severely impairing task sensitivity for detecting those at risk 
of dementing.147 Further to the point, it is arguably unreal-
istic to expect nonoverlapping distributions of cognitive 
performance many years before diagnosis given the large 
interindividual variability in both preclinical AD cases, and 
those who will remain without dementia.148–150 Numerous 
factors can result in cognitive impairment with increasing 
age, leading to false-positive detection including psychiatric, 
metabolic, immunological, and circulatory conditions.151–154 
Moreover, some individuals who will convert to dementia 
show accelerated decline only in close proximity to diagnosis, 
leading to false negatives.149
Change-point models of onset and rate of 
cognitive decline before dementia diagnosis
Given the problem of overlapping distributions for groups 
of preclinical AD and nondemented controls, an obvious 
question concerns what can be done to improve classifica-
tion of those at risk? Based on recent findings from our 
research group, we argue that facilitating early disease 
identification and targeting successful intervention requires 
moving beyond static mean-difference comparisons at one 
point in time to consideration of the relative onset and 
rate of   cognitive decline across a continuum of cognitive 
measures.155 To examine these issues, Thorvaldsson and 
colleagues employed data from two population-based 
Swedish longitudinal studies of aging.155 Participants from 
the age-heterogeneous Kungsholmen Project (Stockholm, 
Sweden) were aged 75 years or older and completed up to 
5 measurement occasions (417 dementia cases and 249 non-
cases). The Gerontological and Geriatric Population Studies 
(Gothenburg, Sweden) included participants who were all 
initially 70 years of age and who were followed for up to 13 
retest occasions spanning 30 years (113 dementia cases and 
272 noncases). A series of linear mixed change-point models 
(see Hall, Lipton, Sliwinski, and Stewart, 2000156) were fit Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
141
integrated management of dementia
to numerous cognitive outcomes. These piecewise models 
estimated two slopes, permitting the knot of the spline (the 
change point) to vary across models in 1-month increments. 
Prior to the knot, time was parameterized as a function of 
chronological age (years since birth from each individual 
measurement). In contrast, following the knot, time was 
specified as a function of time to dementia diagnosis (years 
to diagnosis from each individual measurement). A profile 
likelihood method was then employed to select the best fit-
ting change point spanning a range from 1 month to 10 years 
prior to diagnosis (eg, 3.1 years before diagnosis, 3.2 years 
before diagnosis, 3.3 years before diagnosis). These system-
atic model fit comparisons facilitated the identification of 
the average transition point that best differentiated between 
normative age-related cognitive decline and accelerated 
decline during the preclinical phase.
Thorvaldsson et al reported that the earliest preclinical 
deficits, around 9 years before diagnosis, were observed 
for cognitive correlates of dementia pathology (episodic 
memory) as well as more executively demanding tasks (eg, 
visuospatial ability, processing speed).155 Notably, how-
ever, as nondemented elderly individuals also exhibited 
decline on these tasks, the relative magnitude of cognitive 
changes for the preclinical cases was only modestly incre-
mented. Consistent with expectation, tasks that exhibited 
the earliest onset of cognitive decline did not also exhibit 
the fastest rate of change. Rather, the most precipitous 
estimates of decline were observed for tasks that are at least 
somewhat resistant to age-related decline such as category 
fluency – a knowledge-based task that incorporates both 
fluid and crystallized abilities. Such patterns suggest that 
tasks incorporating both fluid and well-preserved crys-
tallized abilities may facilitate discrimination between 
preclinical cases vs noncases, but only in close proximity 
to incident diagnosis.
Onset versus rate of change
In light of these findings underscoring that onset and rate of 
change in the prodromal period vary as a function of cognitive 
domain, another critical question concerns which character-
istic to focus on for increasing sensitivity of detecting those 
at risk of dementing. As with most questions, the answer 
depends on whether an individual’s emphasis concerns clini-
cal practice or basic research. A general practitioner inter-
ested in the health of an individual patient should place more 
emphasis on early detection, and thus differentially focus on 
onset. Based on our findings, this would mean targeting early 
behavioral changes in process-based measures of cognition 
(eg, episodic memory) that exhibit impairments up to 10 or 
more years prior to diagnosis. Of course, clinical detection 
of such onset in change requires knowledge of baseline 
performance and repeated within-person assessments, and 
even then may prove difficult to detect as normative age-
related changes are also typically observed for these same 
measures. In the Thorvaldsson et al study, for example, 
episodic memory decline in the prodromal phase was only 
accelerated by a factor of 2 relative to decline observed dur-
ing normal aging.155
In contrast, those focusing on more basic research (eg, 
targeting individuals at greatest-risk of converting to AD 
for use in clinical trials research, identifying candidates for 
aggressive pharmacological intervention) may differentially 
focus on accelerated rate of change (rather than onset) for 
select cognitive domains. In particular, our findings suggest 
that verbal fluency may be a particularly important measure 
for increasing sensitivity of detection for those at risk of 
dementing. Verbal fluency shows very little age-related 
change, but when change is finally manifest during the 
prodromal period within 6 years of diagnosis, performance 
decline accelerates by a factor of 5 or more relative to normal 
aging. Indeed, clinical trials research might consider adopt-
ing a multivariate approach where at-risk participants are 
selected on the basis of both onset (individuals exhibit early 
change in episodic memory consistent with AD etiology) as 
well as change (individuals with episodic deficit who also 
show accelerated decline in verbal fluency); such an approach 
is likely to improve sensitivity of identifying those at greatest 
risk of converting.
Preclinical cognitive deficits  
and threshold models
Fundamental tenets of threshold models of cognitive impair-
ment are consistent with both the Thorvaldsson et al findings, 
demonstrating inflection points that differentiate between 
normative age-related cognitive decline vs more accelerated 
decline during the prodromal period in proximity to diagno-
sis, and the Bäckman et al meta-analysis demonstrating that 
cognitive function is more strongly affected in proximity to 
diagnosis.147,155 Further, the concepts of cognitive reserve 
as well as compression of morbidity are both consistent 
with initial trajectories of change that are gradual, fol-
lowed by more pronounced cognitive decline in proximity 
to diagnosis.157–159 For example, Stern’s notion of cognitive 
reserve was developed to facilitate explanation on the modest 
association between the amount of underlying AD pathology 
and observed behavioral deficit.159 Cognitive reserve is said Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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to reflect the amount of neuropathology that can be accrued 
prior to reaching a critical threshold beyond which cognitive 
deficits are manifest.159 Educational attainment in particular 
has been viewed as an index of cognitive reserve, with recent 
findings clearly demonstrating the aforementioned threshold 
effects. Hall et al, for example, showed that those with more 
years of education (12+) did not exhibit cognitive decline 
onset until close proximity to dementia diagnosis relative to 
a low-educated group (less than 7 years) who would subse-
quently dement.157 However, upon reaching their threshold 
for pathology burden, the rate of cognitive impairment was 
steeper for the high-educated group. Thus, later disease onset 
appears to be associated with greater disease burden, manifest 
as accelerated cognitive loss (ie, steeper prodromal slopes) 
once decline occurs.
Future research
In light of the meta-analytic findings by Bäckman et al, it 
is apparent that prospective identification is not facilitated 
through solitary use of cognitive measures that exhibit large 
mean differences between dementia cases and controls years 
before diagnosis.147 This is because the distributions between 
the two groups still overlap to a large extent (.40%) for 
individual cognitive domains such as episodic memory or 
executive functioning. To increase sensitivity of early detec-
tion, Small et al suggest that future research incorporates the 
following improvements.145 First, these authors emphasize 
that multifactorial prediction models are required to improve 
early detection. Evidence suggests that early detection is 
improved considerably upon inclusion not only of episodic 
memory tasks, but also indicators of executive function-
ing and semantic memory.160,161 Next, in service of better 
differentiating between cases and controls, future research 
should also supplement such cognitive markers with other 
markers linked to dementia incidence. These multivariate 
models and their corresponding interactions could include 
biomarkers such as brain volumetrics, amyloid deposition, 
and white-matter alterations, as well as genetic markers, 
subjective memory complaints, social isolation, and life-
style factors such as lack of intellectual engagement or low 
physical activity levels.149,162–169 A key challenge for future 
research will be to ascertain whether specific combinations 
of these biological, social, cognitive, genetic, and clinical 
markers increase identification of those at risk of   dementia. 
To the extent that protective characteristics (eg, high 
  education, active lifestyle) mask the early signs of AD and 
delay the clinical onset, effective multivariate (multistage) 
approaches for facilitating detection will be essential given 
the reduced time window between onset of preclinical decline 
and subsequent diagnosis.170 However, an alternate view is 
that delaying the clinical manifestation of AD by just 2 years 
could significantly reduce the total number of AD cases as 
well as helping to lower healthcare costs.171 This latter view 
underscores the critical need to identify sensitive early indi-
cators of those at risk, and then to target interventions such 
as health or behavior promotion strategies (eg, physical or 
cognitive lifestyle interventions), which may successfully 
delay (or prevent) onset of dementia. Finally, given the 
importance of understanding the natural history of AD pro-
gression, more sophisticated longitudinal designs should be 
adopted for the study of cognitive change during the preclini-
cal period through to dementia onset. In particular, including 
multiple measurement occasions before diagnosis is required 
to better identify the onset of cognitive decline during the 
prodromal period, as well as to quantify the magnitude of 
acceleration. Multiwave datasets and linear mixed models 
may also identify whether select dementia correlates increase 
or decrease in importance in proximity to diagnosis.145 Such 
differentiation may help differentiate between disease risk 
factors vs precipitating factors.
Summary: toward a paradigm shift  
in dementia care for the 21st century
The preceding review highlights the many advances over 
the past few decades that aid our understanding of dementia 
epidemiology and its clinical presentation. It outlines vari-
ous multidisciplinary treatments, including pharmacological 
and nonpharmacological treatment, and addresses significant 
management challenges. Demographic projections under-
score the potential burden that the various dementias pose for 
healthcare in the coming 20 years. Dementia prevalence will 
continue to increase in concert with increased life expectancy 
and improved medical care. Unequivocally, clear advances 
have been made in dementia diagnosis, identification of 
associated risk factors, as well as management and care. 
However,   effective pharmacological treatments that target 
the underlying neuropathology and alter the disease course 
remain elusive.
At least in the near term, we can argue that dementia is as 
much about social policy and governance as it is about medi-
cine or neuropsychology. Given the progressive nature of the 
disease, it will be necessary to target preventive as opposed 
to reactive interventions. Improved policy initiatives should 
target public education documenting specific risk factors 
for dementia from early- and mid-life, as well as lifestyle 
interventions (eg, health or behavior promotion strategies) Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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that can potentially delay or prevent the disease. In the United 
States, for example, delaying the clinical manifestation of 
dementia by 2 years would reduce the total number of AD 
cases by approximately 600,000.171 Based on increasing 
prevalence projections in Canada, the Alzheimer Society 
of Canada (2010) Rising Tide report projects the total 
economic burden of dementia to double each decade, 
increasing from approximately $15 billion (CAD) per year 
in 2008 to $153 billion (CAD) per year by 2038.172 Clearly, 
delaying the onset of dementia by even several years would 
have considerable impact on both disease prevalence as 
well as associated healthcare expenditures. To realize such 
benefits, policy makers should place continued emphasis 
on dementia research, as well as renewed focus on public 
education initiatives (eg, increased as opposed to decreased 
emphasis on physical education programs in primary and 
secondary school) that promote protective and enduring 
lifestyle behaviors.
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